Novo Nordisk is deepening its bet on Amazon’s AI stack. The Danish drugmaker has named AWS its preferred cloud provider and strategic AI partner, extending their work together into drug discovery through agents for target identification, therapy design, and research workflows, plus a co-innovation hub at its London facility.
The hub puts AWS engineers, AI specialists, and applied scientists in the same building as Novo Nordisk researchers, with the goal of cutting handoffs between computational analysis and lab work as candidates move through early development. Thilde Hummel Bogebjerg, the company’s enterprise IT and quality chief, said real impact comes from pairing AI technology with deep scientific expertise and a clear focus on patients.
Novo Nordisk already runs a generative AI platform on Amazon Bedrock used by over 25,000 employees for more than 2,500 use cases, and one system processes roughly 140,000 documents and 26,000 prompts a month. The new agreement adds Amazon Bio Discovery, which exposes more than 40 biological AI models that agents can coordinate to find targets, design therapies, and rank candidate drugs before lab synthesis and testing.
Matt Garman, AWS’s CEO, said the companies aim to shorten drug discovery timelines and apply findings across therapeutic areas. The deal does not make Amazon exclusive, though: OpenAI and Denmark’s Gefion supercomputer remain part of Novo Nordisk’s AI toolkit.
